Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Optimization of the Patient Care Pathway in Immuno-oncology
- Status
- COMPLETED
- Phase
- NA
Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma
- Status
- COMPLETED
- Phase
- NA
Post-ATU Study of Nivolumab
- Status
- COMPLETED
- Phase
- N/A
EPR Tumor Oximetry With CE India Ink
- Status
- TERMINATED
- Phase
- N/A
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
- Status
- UNKNOWN
- Phase
- PHASE4
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
- Status
- TERMINATED
- Phase
- PHASE2
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Status
- COMPLETED
- Phase
- PHASE1
The French E3N Prospective Cohort Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
REO13 Melanoma With of Without GM-CSF
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
- Status
- TERMINATED
- Phase
- PHASE1
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
- Status
- TERMINATED
- Phase
- PHASE2